Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.
Transcript:
Robert L. Coleman, MD, FACOG, FACS:When pembrolizumab [Keytruda] came on the scene in endometrial [carcinoma], we got this indication. In the dMMR [mismatch repair–deficient], it was pan-tumor. It didn’t have an indication. It subsequently converted into an indication for endometrial cancer. Dostarlimab [Jemperli], another immune checkpoint inhibitor, was studied in a trial called GARNET. It turned out to be large study that had 2 cohorts. One was in the dMMR patient population, and 1 was in the pMMR [mismatch repair–proficient] population. [The trial] ended up having a large sample size. We’ve seen several reports of this, and ultimately the data from this trial also led to a disease-specific indication in endometrial cancer because of its outcomes.
It was very similar in its outcomes, very similar with the types of patients who were treated. Its objective response rate was north of 40%. The duration of response was also quite long. What is a little different in this trial is that if you look at the curves, there’s a bit of a sharper curve down to the 50% mark. The median progression-free survival in this trial is around 6 months as opposed to 12 with pembrolizumab. But that’s misleading because the 1- and 2-year progression rates are almost identical. It’s a very L-shaped curve. There may be a second population that’s very immune, sensitive, or responsive, and that was nicely demonstrated. The adverse events are very consistent in our experience. This is a much larger trial, but we saw what we expected to see in this study. We’re very nice with that.
Transcript edited for clarity.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
Ghamande Reviews Latest Chemoimmunotherapy Trials for Endometrial Cancer
March 19th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Sharad A. Ghamande, MD, discussed the significance of the NRG-GY018/KEYNOTE-868 and RUBY trials of immune checkpoint inhibitor plus chemotherapy in patients with advanced endometrial cancer.
Read More